Original Study 329 Team
MARTIN B. KELLER, M.D.
|
Brown University Martin B. Keller Professor Emeritus of Psychiatry and Human Behavior Martin_Keller@brown.edu Martin Keller has made major research contributions to the understanding and treatment of mood disorders. He has performed research on the longitudinal course and neuropsychopharmacology of affective disorders and anxiety disorders and on the causes, pathophysiology, treatment, and prevention of depression. He has received more than 20 research grant awards from the National Institutes of Health (NIH) and numerous grants from research foundations and the pharmaceutical industry. In 2009, Dr Keller was investigated by the US Senate Finance Committee, led by Senator Chuck Grassley, as one of a number of medical academics with a serious conflict of interest in his medical research, because of money received from pharmaceutical companies. |
NEAL D. RYAN, M.D.
|
University of Pittsburgh Department of Psychiatry 3811 O’Hara St. Pittsburgh PA 15213 Phone: 412-383-5477412-383-5477 Fax: 412-383-5426 ryannd@upmc.edu Neal Ryan, MD, is one of the nation’s leading experts on pediatric mood and anxiety disorders. He has led large-scale studies of behavioral changes in children and adolescents diagnosed with mood disorders, and he has investigated the effectiveness of medications and various other treatments, including innovative cognitive-behavioral therapies. Dr. Ryan’s ongoing studies of the pharmacological treatment of unipolar and bipolar depression in adolescents have inspired many graduate students to pursue careers in child and adolescent psychiatry. He is currently principal investigator on a large NIMH-funded project titled “Psychobiology of Childhood Anxiety and Depression.” He has co-authored numerous scholarly articles and remains an important public voice on the causes and treatment of mental health disorders in children and adolescents. In 2009, Dr Ryan was investigated by the US Senate Finance Committee, led by Senator Chuck Grassley, as one of a number of medical academics with a serious conflict of interest in his medical research, because of money received from pharmaceutical companies. |
MICHAEL STROBER, PH.D.
|
UCLA David Geffen School of Medicine Work Phone Number: (310) 825-2982 Mailing Address: 760 Westwood Plaza Mail Code 175919 Los Angeles, CA 90095 USA Work Email Address: mstrober@mednet.ucla.edu Eating Disorders Program Director, Eating Disorder Program Director, Inpatient Child and Adolescent Service Professor in Residence, Psychiatry and Biobehavioral Sciences Member, Semel Institute for Neuroscience and Human Behavior Detailed Biography:Michael Strober is a clinical psychologist who has served on the UCLA School of Medicine faculty since he joined the Department of Psychiatry in 1975. He became a full professor in 1989 and has been Director of the Eating Disorders Program at the Neuropsychiatric Institute since 1982, and Director of the Adolescent Mood Disorders Program since 1989. Dr. Strober earned his B.A. in Psychology with High Honors at Queens College of the City University of New York in 1971, and his M.S. and Ph.D. with distinction in Clinical Psychology at the University of Pittsburgh. Dr. Strober is past President of the Eating Disorders Research Society, and is a founding Fellow of the Academy for Eating Disorders and the American Society of Clinical Psychopharmacology. He is actively involved in medical education and has served as a consultant to the National Institute of Mental Health and the Institute of Medicine. |
|
RACHEL G. KLEIN, PH.D.
|
Fascitelli Family Professor of Child and Adolescent Psychiatry, Department of Child and Adolescent Psychiatry;Professor, Department of Psychiatry Child and Adolescent Psychiatry Contact Info Address 1 Park Avenue New York, NY 10016Phone: 646/754-4931Email: Rachel.Klein@nyumc.org |
STAN P. KUTCHER, M.D. |
Dalhousie University Professor, Department of PsychiatryContact information Email: stan.kutcher@dal.ca Phone: 902-470-6598 Mailing Address: IWK Health Centre 5850/5980 University Ave. PO Box 9700 Halifax, NS B3K 6R8In 2011, Dr Kutcher ran in Halifax as the Liberal candidate in the federal election. Author of Ghostwritten Study Runs for Parliament in Canada. In April, as reported by Halifax Media Co-op, The Coast (http://www.thecoast.ca/) published an article, Retraction Reaction, which stated that Kutcher and the Study 329 research team “essentially lied” to the public about what the study results really showed.On April 27, 2011 Dr. Kutcher issued a press release entitled: Kutcher Demands Retraction. With reference to the Coast article, it read, in part:“Commenting on the story, Dr. Stan Kutcher, Liberal candidate for Halifax, said: “It comes as a great surprise that The Coast is confusing opinion with science – this is something we are more accustomed to hear from the American right wing than the Canadian left wing.”Kutcher has demanded a retraction. The confusion could be costly for The Coast. Dr. Kutcher intends to launch a defamation suit against the publication as a result of its inflammatory innuendo and the potential to damage his personal, professional and political reputation.Dr Kutcher got his retraction, and an apology. He was defeated in the May 2, 2011 election by NDP candidate Megan Leslie. |
BORIS BIRMAHER, M.D.
|
University of Pittsburgh Department of Psychiatry 3811 O’Hara St. Pittsburgh PA 15213Phone: 412-246-5788412-246-5788 Fax: 412-246-5230 birmaherb@upmc.edu |
OWEN RINZO HAGINO, M.D.
|
Department of Child & Adolescent Psychiatry, Children’s Pennsylvania (American Academy of Child and Adolescent Psychiatry) to 2000
Dr. Owen Hagino is a psychiatrist in Malvern, Pennsylvania. He received his medical degree from University of Hawaii John A. Burns School of Medicine and has been in practice for 27 years. 9 Great Valley Pkwy Phone: (610) 889-8426 |
|
HAROLD S. KOPLEWICZ, M.D.
|
President, Child Mind Institute 445 Park Avenue (entrance on 56th Street) New York, NY 10022General Inquiries: 212.308.3118 | info@childmind.org Harold S. Koplewicz, MD, founding president of the Child Mind Institute, is one of the nation’s leading child and adolescent psychiatrists. He is widely recognized as an innovator in the field, a strong advocate for child mental health, and a master clinician. He has been repeatedly recognized in America’s Top Doctors, Best Doctors in America, and New York Magazine’s “Best Doctors in New York,” and was named one of WebMD’s 2014 Health Heroes for his activism on behalf of children with psychiatric or learning disorders.Dr. Koplewicz and Brooke Garber Neidich founded the Child Mind Institute in 2009. Dr. Koplewicz leads the Institute’s mission to offer evidence-based clinical care; visionary research engaging the global scientific community in the discovery of more effective treatments; trustworthy information and resources to educate and empower parents; and passionate advocacy to destigmatize childhood psychiatric disorders. Dr. Koplewicz was Director of the Nathan S. Kline Institute for Psychiatric Research (NKI) from 2006-2011, the third person and the first child and adolescent psychiatrist to hold that position since the institution’s founding in 1952. At NKI he expanded the research portfolio to include child and adolescent psychiatric research. Dr. Koplewicz founded the NYU Child Study Center in 1997 and served as its director for 12 years. He was the first Arnold and Debbie Simon Professor of Child and Adolescent Psychiatry. In 2006, the NYU Child Study Center was established as the second independent department of child and adolescent psychiatry in the country, and Dr. Koplewicz was appointed as its first chair. Under his leadership, the NYU Child Study Center made tremendous contributions to the field through expert clinical care, a robust research portfolio, and advocacy for child mental health. A graduate of Albert Einstein College of Medicine, Dr. Koplewicz completed his psychiatric residency at New York Hospital Westchester Division, a fellowship in child psychiatry at Columbia University’s College of Physicians and Surgeons, an NIMH research fellowship in child psychiatry at the New York State Psychiatric Institute, and the Executive Program in Health Policy and Management at Harvard University’s School of Public Health. An internationally respected psychiatrist, Dr. Koplewicz is the recipient of many awards, including the 1997 Exemplary Psychiatrist Award from the National Alliance of the Mentally Ill; the 1998 Reiger Service Award from the American Academy of Child and Adolescent Psychiatry in recognition of his work in the development of school-based mental health programs; the 1999 Humanitarian Award from Marymount Manhattan College; the 2000 American Grand Hope Award from the Aprica Childcare Institute; the 2002 Catcher in the Rye Award from the American Academy of Child and Adolescent Psychiatry; and the 2009 American Psychiatric Association McGavin Award for lifetime contributions to child psychiatry. |
|
GABRIELLE A. CARLSON, M.D.
|
Gabrielle A. Carlson, M.D. – Biography
Gabrielle A. Carlson, M.D., has been professor of Psychiatry and Pediatrics and Director of the Division of Child and Adolescent Psychiatry at State University of New York at Stony Brook since 1985. She did her undergraduate training at Wellesley and subsequently obtained her MD degree from Cornell University Medical College. She did her adult psychiatry training at Washington University in St. Louis and at the National Institutes of Mental Health. She completed a fellowship and research fellowship in Child and Adolescent Psychiatry at UCLA where she subsequently taught on the faculty. Dr. Carlson specializes in childhood psychopathology and psychopharmacology in general, and the subjects of childhood and adolescent depression and bipolar disorder, specifically. She has written over 200 papers and chapters on those subjects and has co-authored two books, Affective Disorders in Childhood Adolescence (Spectrum Publications) and Psychiatric Disorders in Children and Adolescents (W.B. Saunders). Her research interests include the phenomenology, long term follow up and treatment of young people with bipolar disorder, and the relationship between behavior disorders, like ADHD, developmental disorders and mood disorders. Her most recent grants have focused on those questions. Dr. Carlson is active in the psychiatry community. She has served on many national committees. These include the APA committee to evaluate DSM III, the DSM IV Task Force on Child and Adolescent Psychiatric Disorders, Emslie Institute of Medicine committees, and various review committees for the National Institute of Mental Health. She has been named in Best Doctors in America and Good Housekeeping’s Best Mental Health Experts. She was recently awarded the APA’s Blanche F. Ittleson Award for research in child and adolescent psychiatry and the Hulse Award for Child and Adolescent Psychiatry in New York. She was president of the International Society for Research in Child and Adolescent Psychopathology and will become program chair of the American Academy of Child and Adolescent Psychiatry in 2011. |
GREGORY N. CLARKE, PH.D.
|
Kaiser Permenante Centre for Health Research Senior Investigator Assistant Program DirectorE-mail: Greg.Clarke@kpchr.org Dr. Gregory Clarke‘s areas of interest include depression prevention and treatment, child and adolescent mental health and treatments, and treatment of patients who have both substance abuse and mental disorders. Dr. Clarke has been the principal investigator and co-investigator on several grants funded by the National Institute of Mental Health, conducting controlled-outcome trials of depression treatment and prevention in at-risk populations. Some of his most recent controlled trials have examined the costs and clinical outcomes of preventing and treating depression in adolescent offspring of depressed parents enrolled in an HMO; the medication and psychotherapy treatment of depression in adolescents who have failed to respond to an initial course of selective serotonin reuptake inhibitor anti-depressant medication; treatment of depression in adults who are also receiving outpatient treatment for alcohol addiction; simultaneous psychotherapy and medication for depressed adolescents treated in primary care; and Internet self-care programs for depressed adults and adolescents. Dr. Clarke has conducted mental health research for 20 years. He received his PhD in clinical psychology from the University of Oregon in 1985. |
|
GRAHAM J. EMSLIE, M.D. |
UT Southwestern Medical Centre Charles E. and Sarah M. Seay Chair in Child Psychiatry 5323 Harry Hines Blvd., Dallas, Texas 75390 214-456-5918 Dr. Emslie obtained his undergraduate degree and M.D. at Aberdeen University in Aberdeen, Scotland in 1974. Dr. Emslie did his internship at Aberdeen Hospitals, Scotland in general medicine and neurosurgery. He did his residency training in general psychiatry at the University of Rochester, NY and child psychiatry at Stanford University, where he also completed a research fellowship. Dr. Emslie joined the U.T. Southwestern Faculty in 1981. He has served as Director for both the inpatient and outpatient units of Children’s Medical Center’s Psychiatry Division. Currently, Dr. Emslie is the Chief of Adolescent Psychiatry program at UT Southwestern and Children’s Medical Center of Dallas. Dr. Emslies clinical expertise is in the area of child and adolescent depression. Dr. Emslies research foci are in the areas of conducting efficacy and effectiveness trials with medications and psychotherapy for children and adolescents with depression, anxiety disorders, and attention-deficit disorder. He is also involved with developing and evaluating medication algorithm protocols for children and adolescents with depression. Dr. Emslie is active in the following professional organizations: American Academy of Child and Adolescent Psychiatry, American Psychiatric Association, Texas Society of Child and Adolescent Psychiatry, Texas Society of Psychiatric Physicians, Society of Biological Psychiatry, and the International Society for Research in Child and Adolescent Psychopathology. He is also on several committees, including the National Institute of Mental Health (NIMH) Interventions Committee, NIMH Child Council Work Group, and the Corporate Contributions and Research Committee for the American Academy of Child and Adolescent Psychiatry. In addition, he serves on the editorial board for the Journal of the American Academy of Child and Adolescent Psychiatry. He also past President for the Texas Society of Child and Adolescent Psychiatry. Dr. Emslie has written over 60 papers and 17 chapters. He is known internationally for his work in the treatment of pediatric depression. In 2003, he was awarded the Klingenstein Third generation Foundation Award for his work in this field. In 2009, Dr Emslie was investigated by the US Senate Finance Committee, led by Senator Chuck Grassley, as one of a number of medical academics with a serious conflict of interest in his medical research, because of money received from pharmaceutical companies. The committee was concerned that this conflict was behind fraudulent research that resulted in harmful medication, some with little efficacy, being widely prescribed without adequate warnings. |
DAVID FEINBERG, M.D. |
UCLA David Geffen School of Medicine Director, Child and Adolescent Outpatient Evaluation and Treatment Clinic Associate Professor, Psychiatry and Biobehavioral SciencesWork Phone Number: (310) 267-3516 (310) 267-9315Mailing Address: 757 Westwood Plaza, Suite 1320 Ronald Reagan UCLA Medical Center Mail Code 740030 Los Angeles, CA 90095 UNITED STATESWork Email Address: dfeinberg@mednet.ucla.edu David Feinberg, MD, MBA is the chief executive officer of the UCLA Hospital System and associate vice chancellor. Prior to assuming the leadership role of CEO for UCLA Hospitals, Dr. Feinberg was the medical director of the Resnick Neuropsychiatric Hospital (NPH) at UCLA. He has been a faculty member in the Department of Psychiatry at the David Geffen School of Medicine since 1994. He is triple board certified in Child and Adolescent Psychiatry, Adult Psychiatry, and Addiction Psychiatry. Dr. Feinberg also has his master of business administration from Pepperdine University. Dr. Feinberg areas of expertise include Attention Deficit/Hyperactivity Disorder, Adolescent Substance Abuse and the business of medicine. |
|
BARBARA GELLER, MD |
Associate Editor, NEJM Journal Watch Psychiatry
About the NEJM Journal Watch Psychiatry Board |
|
|
Professor of Psychiatry Dalhousie University |
|
No photo available
|
Assistant Professor, University of Toronto Division One: Brain and Therapeutics Division Two: Child and AdolescentContact Information Address: CAMH – College Street Site 250 College Street Toronto, ON M5T 1R8 Room: Ste. 725Telephone: 416-535-8501 x4925 |
WILLIAM H. SACK, M.D. |
OREGON HEALTH AND SCIENCE UNIVERSITY Child and Adolescent Psychiatry 3181 SW Sam Jackson Park Rd Portland, OR 97239 |
|
MICHAEL SWEENEY, PH.D. |
Metropolitan Center for Cognitive Behaviour Therapy (CBT)
Dr. Michael Sweeney is the Director of the Metropolitan Center for Cognitive Behavior Therapy, a private practice center specializing in the treatment of anxiety. Michael prides himself on practical advice for complicated situations. Dr Sweeney was an assistant professor of Clinical Psychology in Psychiatry at Columbia University’s College of Physicians and Surgeons, CBT supervisor at St. Vincent’s Medical Center, and the external reviewer for the Masters CBT program at University College, Dublin, Ireland. Dr. Sweeney is currently an adjunct professor at Teachers College, Columbia University. Michael has lectured nationally and internationally on the use of CBT. |
|
KAREN DINEEN WAGNER, M.D. |
Dr Wagner is the Marie B. Gale Centennial Professor and Vice Chair in the department of psychiatry and behavioral sciences and Director of Child and Adolescent Psychiatry at the University of Texas Medical Branch at Galveston. She is the Child and Adolescent Psychiatry columnist for Psychiatric Times.
Medical/Professional School: S.U.N.Y. at Stony Brook, M.D., Grad: 1984 She was one of two winners of the Colvin Prize for Outstanding Achievement in Mood Disorders Research in 2012. |
|
ELIZABETH B. WELLER, M.D. |
Elizabeth B. Weller, MD, long-time member of Annals of Clinical Psychiatry’s editorial board, succumbed to breast cancer on November 29, 2009, shortly after her sixtieth birthday. At the time of her death, Elizabeth was professor of psychiatry and pediatrics at the University of Pennsylvania (the first woman holding an endowed professorship at the university) and the first chairof the department of child and adolescent psychiatry at Children’s Hospital of Philadelphia. |
|
NANCY C. WINTERS, M.D.
|
First name: Nancy Last name: Winters Degrees: MDAddress: 2311 NW Northrup Street #201 City: Portland State: OR Zip: 97210Phone: 503.243-1444 Graduate and faculty member at the Oregon Psychoanalytic Institute and Center; and a Professor of Psychiatry at Oregon Health & Science University (OHSU). She received her medical training at the Albert Einstein College of Medicine in NY, her adult psychiatry residency training at Yale University, and child/adolescent psychiatry residency at OHSU. She practices psychoanalysis and psychoanalytic psychotherapy in NW Portland, integrating contemporary, developmental, and neuroscience perspectives. With a background in music and the visual arts, she has a special interest in psychoanalytic explorations of creativity. |
|
ROSEMARY OAKES, M.S.
|
No details available. |
|
JAMES P. MCCAFFERTY |
President, Chesapeake Regulatory Group Inc Director-Clinical Research Development and Medical Affairs GlaxoSmithKline plc Position, Clinical Research and Drug Development Training Course James P. McCafferty, BS, currently serves as Director, Clinical Research and Development, for GlaxoSmithKline, and is responsible for US clinical programs for the treatment of Alzheimer¿s disease and clinical development support of marketed central nervous system (CNS) products.James serves as instructor for the DIA Advanced Topics in Clinical Research/Drug Development training course.James earned his BS in Biology from LaSalle University. |
|
SALLY LADEN |
Sally Laden worked for Scientific Therapeutics Information (STI), a Springfield, New Jersey company specializing in pharmaceutical PR and communications. She was the “ghostwriter” of Study 329. As she acknowledged in her 2007 deposition in Cunningham v. Smithkline Beecham, she did not talk to the authors before providing the first draft of the manuscript. |
MINA DULCAN |
Dr. Mina Dulcan is a psychiatrist in Chicago, Illinois and is affiliated with multiple hospitals in the area, including Ann and Robert H. Lurie Children’s Hospital of Chicago and Northwestern Memorial Hospital. She received her medical degree from Penn State College of Medicine and has been in practice for 41 years. She is one of 16 doctors at Ann and Robert H. Lurie Children’s Hospital of Chicago and one of 183 at Northwestern Memorial Hospital who specialize in Psychiatry.
She was the editor of the Journal of the American Academy of Child and Adolescent Psychiatry responsible for publishing Keller et al 2001 S: 312-227-3413 Ann & Robert H. Lurie Children’s Hospital of Chicago Box 10 225 E Chicago Avenue m-dulcan@northwestern.edu Professor in Psychiatry and Behavioral Sciences and Pediatrics, Northwestern University Feinberg School of Medicine. This is a research and educational institution. |
Share this:
We have already had the trial by media here as Glaxo thinks it’s all gone away…and the media mostly perpetuate ‘benefits/myths’ much to our chagrin.
IBOM or as I call him, OneBrilloleMickey, has mentioned these conflicts and ghosted ‘originals’ many times, over the years, so much so, that they feel like ‘old friends’.
Perhaps we now ought to extend our thinking to what lines will be written in response in the BMJ and elsewhere and how it will be confronted.
The momentum is increasing
Thank you
Nice as nice can be. Upstanding citizens. Accomplished. Praiseworthy. Cream of the crop. The kind society needs more of. Award-winning superstars. You just don’t get any better than this. If you can’t trust these people with your health and your life who can you trust?
Here are the perfect followers to follow. Expert followers to follow. Well-meaning leader/followers who participate recklessly in this reckless system because this is what everybody does–this is how business is done.
Every single healthcare institution has a line-up of followers just like this.
I wonder if any of them regret it ? If they think about the deaths and misery they helped create ?
Probably too busy counting their pennies to see if they can book a special trip to Space, courtesy of Special Arrangements Holidays, to hide until all this is over!!! Only trouble is, we’ll have a welcoming party awaiting their return however long it takes!
This is the line up of the real marketing strategists for Paxil– GSK did not prescribe these drugs to kids based on rating scales. and vague symptoms of adolescent adjustment crisis. GSK did not claim that adverse effects, like manic episodes- was the unmasking of latent bipolar disorder.
I think it is important to focus on this line up. GSK certainly did. And remember, all of these prestigious academics willfully sold their names and sold out their professions —AND stuck by the story GSK wrote for them to tell.
I really think, Lisa, that we have lost much moral fibre in the world today.
Senior people, very senior people are caught out lying every day, in politics, in business, in most aspects of life today.
So, it has to trickle down to some leading lights who have made their careers in the Mental Health Conspiracy to Care.
These affluent people, I think, get carried away with a superior sense of self and the higher up they get and the more well known they become, I think, they have persuaded themselves that their niche is bombproof because they are not unintelligent and their colleagues, on this level, have equally chosen to do the same.
Strength in numbers of miscreants such as this can take over the world, if we are not careful.
If we can pull them up now, with these revelations, it will be a unique stand not only with honesty put back under the spotlight and regaining the moral high ground, but, that the systematic pull of pharma pay offs and ghosting is a criminal enterprise.
They will become angry to be so accused, I am sure, but, who cares as long as we are completely aware of what they are up to.
If I have seen this way down the line with my own doctors behaviour, it is hardly surprising that the whole system is permeated with one upmanship and incredible arrogance, and, in health, this is particularly disturbing as young and older lives are at stake.
So, do they regret?
I doubt that concept even exists in the minds of people like this.
They have a film over their eyes and it is not the one that we are watching……
Watching the MHRA performances, on film, is particularly cringe worthy.
Who are these people, what are these people, why do they do it?
Why did they choose Healthcare over a different profession?
AKA Hall of Shame.
No other words needed.
The one time Keller regretted anything was during the FBI interview. he might be a Bright man, but he wasn’t comfortable being pinned down by people with experience with hardened crooks.
On the whole, I Think they don’t get the implications of their actions. They posess some kind of inability to grasp what a suicide really means.
As I said Before: these advert events aren’t skin-rashes, these are Death and tragic to people.
This past week has been filled with so much good Reading, the ‘Timeline’ is awesome, the famous grouse lecture the same. I get filled with the sense of hope.
http://www.alltrials.net/news/who-calls-for-data-sharing-by-default-in-public-health-emergencies/
https://twitter.com/thinkHEL/status/639811296427438081/photo/1
We have a vacancy for a Campaigns & Policy Officer to work on #AllTrials, #AskforEvidence & more. Details: http://bit.ly/1JGMaJg #Scicomm
Shortlisted candidates will be required to complete a written task by 24th September. Interviews: 1st/2nd October. It is essential that you explore our work before applying http://www.senseaboutscience.org. –
:()
Written task:
Why is Sense about Science supporting GlaxoSmithKline?
:()
The Serious Fraud Office is looking….for…….
https://report.sfo.gov.uk/sfo-confidential—provide-information-in-confidence.aspx
With regard to….
https://truthman30.wordpress.com/2015/09/08/uk-serious-fraud-office-and-the-gsk-3/
It would be nice if Seroxat fatalities were dealt an honest hand….there’s nowhere else to go as the other Government Agencies ie MHRA/MHC/NICE have made it quite clear that they are not interested…..